Your browser doesn't support javascript.
loading
Final report on plasma ctDNA T790M monitoring during EGFR-TKI treatment in patients with EGFR mutant non-small cell lung cancer (JP-CLEAR trial).
Naka, Go; Yokoyama, Takuma; Usui, Kazuhiro; Ishida, Hiroo; Kishi, Kazuma; Uemura, Kohei; Ohashi, Yasuo; Kunitoh, Hideo.
Afiliación
  • Naka G; National Center for Global Health and Medicine, Tokyo, Japan.
  • Yokoyama T; Kyorin University Hospital, Mitaka, Tokyo, Japan.
  • Usui K; NTT Medical Center, Tokyo, Japan.
  • Ishida H; Showa University Northern Yokohama Hospital, Yokohama, Kanagawa, Japan.
  • Kishi K; Toho University Omori Medical Center, Tokyo, Japan.
  • Uemura K; The University of Tokyo, Tokyo, Japan.
  • Ohashi Y; Chuo University, Tokyo, Japan.
  • Kunitoh H; Japanese Red Cross Medical Center, Tokyo, Japan.
Jpn J Clin Oncol ; 52(7): 791-794, 2022 07 08.
Article en En | MEDLINE | ID: mdl-35323965
Osimertinib is active against T790M-positive epidermal growth factor receptor mutant non-small cell lung cancer. We enrolled 122 sensitive epidermal growth factor receptor mutant non-small cell lung cancer patients who were planned to receive or were receiving first-/second-generation epidermal growth factor receptor tyrosine kinase inhibitors without disease progression and monitored plasma T790M every 1-2 months using the cobas® EGFR Mutation Test v2. We previously reported the concordance between T790M status in plasma and tissue. This is the final report on the sensitivity of plasma T790M and the efficacy of sequential osimertinib. The sensitivity was 21.1% (95% confidence interval: 6.1-45.6%). The best overall response was 25.0% (95% confidence interval: 9.8-46.7) in the plasma T790M-positive group and 28.6% (95% confidence interval: 8.4-58.1) in the plasma T790M-negative but tissue T790M-positive group. Median progression-free survival was 7.9 months (95% confidence interval: 4.7-17.5) for the former and 4.4 months (95% confidence interval: 3.0-N.E.) for the latter, with no statistically significant difference (P = 0.74).
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / ADN Tumoral Circulante / Neoplasias Pulmonares / Antineoplásicos Límite: Humans Idioma: En Revista: Jpn J Clin Oncol Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Carcinoma de Pulmón de Células no Pequeñas / ADN Tumoral Circulante / Neoplasias Pulmonares / Antineoplásicos Límite: Humans Idioma: En Revista: Jpn J Clin Oncol Año: 2022 Tipo del documento: Article País de afiliación: Japón Pais de publicación: Reino Unido